Pamela Villalobos
Papers
1
Total Citations
49
H-Index
1
About
Pamela Villalobos is a leading cancer biologist whose research focuses on cell cycle regulation, CDK inhibitors, and the mechanisms of anaphase catastrophe in lung cancer. Her seminal work on next-generation CDK2/9 inhibitors has fundamentally advanced our understanding of how targeted therapies can exploit centrosome amplification in tumor cells. In her highly cited 2016 study (49 citations), Villalobos demonstrated that the novel CDK2/9 inhibitor CCT68127 induces multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes—a phenomenon she helped define as anaphase catastrophe. This work built upon earlier findings with first-generation CDK2/7/9 inhibitor seliciclib (CYC202), establishing a critical framework for developing more selective and potent CDK inhibitors. Her research bridges fundamental cell biology with translational oncology, providing mechanistic insights that inform the design of next-generation cancer therapeutics. Villalobos’s contributions have been instrumental in characterizing how CDK inhibition selectively targets cancer cells with mitotic vulnerabilities, opening new avenues for precision medicine in lung cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016